Adrenal Insufficiency Induced by Continued Abiraterone Acetate Use in a Prostate Cancer Patient in Remission: The Dangers of Unmonitored Long-Term Therapy Without Corticosteroids
This case report presents a rare occurrence of adrenal insufficiency induced by Zytiga (abiraterone acetate) in a patient with high-risk localized prostatic adenocarcinoma. Abiraterone acetate is a potent, selective and irreversible CYP17A1 inhibitor and is commonly used in the treatment of prostate...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/32/3/156 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850203784326676480 |
|---|---|
| author | Ahmed S. Mohamed Ahmad R. Awwad Angel Ann Chacko Shraboni Dey Brianna Braithwaite Ruchi Bhuju Sameh Elias |
| author_facet | Ahmed S. Mohamed Ahmad R. Awwad Angel Ann Chacko Shraboni Dey Brianna Braithwaite Ruchi Bhuju Sameh Elias |
| author_sort | Ahmed S. Mohamed |
| collection | DOAJ |
| description | This case report presents a rare occurrence of adrenal insufficiency induced by Zytiga (abiraterone acetate) in a patient with high-risk localized prostatic adenocarcinoma. Abiraterone acetate is a potent, selective and irreversible CYP17A1 inhibitor and is commonly used in the treatment of prostate cancer, but it can cause various endocrine side effects, especially if not used concurrently with the appropriate treatment. The clinical implications of this adverse event and management strategies are discussed here in this case report to raise awareness about this potential risk in patients with prostate cancer undergoing treatment with abiraterone acetate, especially when used in an erroneous manner without monitoring. |
| format | Article |
| id | doaj-art-23570201c0ec41ad83eb9ada3c1eaff6 |
| institution | OA Journals |
| issn | 1198-0052 1718-7729 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj-art-23570201c0ec41ad83eb9ada3c1eaff62025-08-20T02:11:25ZengMDPI AGCurrent Oncology1198-00521718-77292025-03-0132315610.3390/curroncol32030156Adrenal Insufficiency Induced by Continued Abiraterone Acetate Use in a Prostate Cancer Patient in Remission: The Dangers of Unmonitored Long-Term Therapy Without CorticosteroidsAhmed S. Mohamed0Ahmad R. Awwad1Angel Ann Chacko2Shraboni Dey3Brianna Braithwaite4Ruchi Bhuju5Sameh Elias6Department of Internal Medicine, Hackensack Meridien Health, Palisades Medical Center, North Bergen, NJ 07047, USATransitional Year Program, Hackensack Meridien Health, Palisades Medical Center, North Bergen, NJ 07047, USADepartment of Internal Medicine, Hackensack Meridien Health, Palisades Medical Center, North Bergen, NJ 07047, USADepartment of Internal Medicine, Hackensack Meridien Health, Palisades Medical Center, North Bergen, NJ 07047, USADepartment of Internal Medicine, Hackensack Meridien Health, Palisades Medical Center, North Bergen, NJ 07047, USADepartment of Internal Medicine, Hackensack Meridien Health, Palisades Medical Center, North Bergen, NJ 07047, USAInternal Medicine Program, Hackensack Meridien Health, Palisades Medical Center, North Bergen, NJ 07047, USAThis case report presents a rare occurrence of adrenal insufficiency induced by Zytiga (abiraterone acetate) in a patient with high-risk localized prostatic adenocarcinoma. Abiraterone acetate is a potent, selective and irreversible CYP17A1 inhibitor and is commonly used in the treatment of prostate cancer, but it can cause various endocrine side effects, especially if not used concurrently with the appropriate treatment. The clinical implications of this adverse event and management strategies are discussed here in this case report to raise awareness about this potential risk in patients with prostate cancer undergoing treatment with abiraterone acetate, especially when used in an erroneous manner without monitoring.https://www.mdpi.com/1718-7729/32/3/156abiraterone acetateadrenal insufficiencyprostate cancermineralocorticoid excess syndromeprednisoloneCYP17A1 |
| spellingShingle | Ahmed S. Mohamed Ahmad R. Awwad Angel Ann Chacko Shraboni Dey Brianna Braithwaite Ruchi Bhuju Sameh Elias Adrenal Insufficiency Induced by Continued Abiraterone Acetate Use in a Prostate Cancer Patient in Remission: The Dangers of Unmonitored Long-Term Therapy Without Corticosteroids Current Oncology abiraterone acetate adrenal insufficiency prostate cancer mineralocorticoid excess syndrome prednisolone CYP17A1 |
| title | Adrenal Insufficiency Induced by Continued Abiraterone Acetate Use in a Prostate Cancer Patient in Remission: The Dangers of Unmonitored Long-Term Therapy Without Corticosteroids |
| title_full | Adrenal Insufficiency Induced by Continued Abiraterone Acetate Use in a Prostate Cancer Patient in Remission: The Dangers of Unmonitored Long-Term Therapy Without Corticosteroids |
| title_fullStr | Adrenal Insufficiency Induced by Continued Abiraterone Acetate Use in a Prostate Cancer Patient in Remission: The Dangers of Unmonitored Long-Term Therapy Without Corticosteroids |
| title_full_unstemmed | Adrenal Insufficiency Induced by Continued Abiraterone Acetate Use in a Prostate Cancer Patient in Remission: The Dangers of Unmonitored Long-Term Therapy Without Corticosteroids |
| title_short | Adrenal Insufficiency Induced by Continued Abiraterone Acetate Use in a Prostate Cancer Patient in Remission: The Dangers of Unmonitored Long-Term Therapy Without Corticosteroids |
| title_sort | adrenal insufficiency induced by continued abiraterone acetate use in a prostate cancer patient in remission the dangers of unmonitored long term therapy without corticosteroids |
| topic | abiraterone acetate adrenal insufficiency prostate cancer mineralocorticoid excess syndrome prednisolone CYP17A1 |
| url | https://www.mdpi.com/1718-7729/32/3/156 |
| work_keys_str_mv | AT ahmedsmohamed adrenalinsufficiencyinducedbycontinuedabirateroneacetateuseinaprostatecancerpatientinremissionthedangersofunmonitoredlongtermtherapywithoutcorticosteroids AT ahmadrawwad adrenalinsufficiencyinducedbycontinuedabirateroneacetateuseinaprostatecancerpatientinremissionthedangersofunmonitoredlongtermtherapywithoutcorticosteroids AT angelannchacko adrenalinsufficiencyinducedbycontinuedabirateroneacetateuseinaprostatecancerpatientinremissionthedangersofunmonitoredlongtermtherapywithoutcorticosteroids AT shrabonidey adrenalinsufficiencyinducedbycontinuedabirateroneacetateuseinaprostatecancerpatientinremissionthedangersofunmonitoredlongtermtherapywithoutcorticosteroids AT briannabraithwaite adrenalinsufficiencyinducedbycontinuedabirateroneacetateuseinaprostatecancerpatientinremissionthedangersofunmonitoredlongtermtherapywithoutcorticosteroids AT ruchibhuju adrenalinsufficiencyinducedbycontinuedabirateroneacetateuseinaprostatecancerpatientinremissionthedangersofunmonitoredlongtermtherapywithoutcorticosteroids AT samehelias adrenalinsufficiencyinducedbycontinuedabirateroneacetateuseinaprostatecancerpatientinremissionthedangersofunmonitoredlongtermtherapywithoutcorticosteroids |